This page will reference some new treatments for prostate cancer. Far from being a comprehensive guide to all new treatments, it includes treatments known to people within the Prostate Heidelberg Support Group and which may be of interest to others. The mention of a treatment here should not imply anything about its efficacy relative to other treatments.
Peter MacCallum Centre has new research grants
Peter Mac researchers have received a major funding boost ($5.4m) for two new clinical trials of a game-changing radioactive molecule purpose made to kill prostate cancer cells. The Commonwealth Government and Movember Foundation this week announced a co-investment of $4 million to advance a new targeted therapy pioneered at the Peter MacCallum Cancer Centre called PSMA Theranostics.
The treatment, LuPSMA (Lutetium-177 PSMA-617), uses a radioactive molecule that binds only to prostate cancer cells with minimal impact on neighbouring healthy cells.
This funding will also allow this research alliance to study a new form of immunotherapy called CAR T-cell therapy for men with prostate cancer which does not respond to the Lutetium-177 treatment.
Peter Mac patient Barry Elderfield, who responded favourably to LuPSMA treatment in the original pilot study, said this new funding was a very exciting development. To see the extension of LuPSMA trials to include men with newly-diagnosed advanced metastatic prostate cancer and less advanced cancer is just thrilling.
Video of Professor Hofman addressing the members of Prostate Heidelberg
To view this 45 Minute Video on the latest scanning techniques and treatment for prostate cancer click either of the links that follow –
If you experience problems connecting to these videos try using the CHROME – FIREFOX has known video display problems.